MediWound’s (MDWD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of MediWound (NASDAQ:MDWD) in a research report released on Friday morning,Benzinga reports. The firm currently has a $25.00 target price on the biopharmaceutical company’s stock.

MediWound Price Performance

Shares of MediWound stock opened at $16.72 on Friday. The business has a 50-day simple moving average of $17.24 and a 200 day simple moving average of $17.66. MediWound has a one year low of $11.04 and a one year high of $24.00. The firm has a market capitalization of $180.34 million, a price-to-earnings ratio of -5.77 and a beta of 0.80.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the company posted ($0.24) EPS. On average, sell-side analysts expect that MediWound will post -2.6 EPS for the current year.

Institutional Trading of MediWound

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its position in shares of MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 8,449 shares during the last quarter. State Street Corp lifted its stake in MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 45,529 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in MediWound during the 3rd quarter worth $212,000. Investor AB bought a new stake in shares of MediWound in the 3rd quarter worth $15,750,000. Finally, MetLife Investment Management LLC bought a new stake in shares of MediWound in the 3rd quarter worth $89,000. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.